Determination of therapeutic and toxic plasma concentrations of the antipsychotic drug prothipendyl

Determination of therapeutic and toxic plasma concentrations of the antipsychotic drug prothipendyl - Prothipendyl

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011452

Enrollment

100

Registered

2017-01-26

Start date

2017-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedative agent within psychotic diseases

Interventions

Group 1: 1. Collection of blood samples at undefined time points after the single or chronic intake of prothipendyl (dose undefined) 2. Documentation of co-Medication and time points of intake 3. Dete

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: therapy with prothipendyl

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Detection of plasma concentrations at defined time points after the intake of prothipendyl by high perfromance liquid chromatography mass spectrometry after single or chronic intake.	—

Countries

Germany

Contacts

Public ContactP. Heese

Leitender Oberarzt der Abteilung fürAbhängigkeitserkrankungen und PsychotherapieFacharzt für Psychiatrie und Psychotherapie

Peter.Heese@lvr.de0228 551-2397

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026